Role of C-type natriuretic peptide in polycystic ovary syndrome

Int J Gynaecol Obstet. 2023 May;161(2):601-606. doi: 10.1002/ijgo.14568. Epub 2022 Nov 25.

Abstract

Objective: To evaluate serum C-type natriuretic peptide (CNP) and androgen concentrations in women with polycystic ovary syndrome (PCOS), and compare them with the healthy group.

Methods: The present study was carried out prospectively at the Near East University Hospital, between July 15, 2019 and September 1, 2020. Out of the 90 patients aged between 18 and 40 years old who were enrolled, the final study population consisted of 36 patients with PCOS and 30 healthy women.

Results: Body mass index, free androgen index, serum androstenedione, total testosterone, free testosterone, and CNP were significantly higher and serum sex-hormone-binding globulin level was lower in the PCOS group.

Conclusion: We revealed that serum CNP levels are high in PCOS patients. The mechanism of the relationship between this increase and hyperandrogenism or anovulation is not known, but these findings provide a direction for new studies.

Clinicaltrials: GOV: NCT04006171.

Keywords: C-type natriuretic peptide; hyperandrogenism; polycystic ovary syndrome.

MeSH terms

  • Adolescent
  • Adult
  • Androgens
  • Female
  • Humans
  • Hyperandrogenism*
  • Natriuretic Peptide, C-Type
  • Polycystic Ovary Syndrome*
  • Testosterone
  • Young Adult

Substances

  • Androgens
  • Natriuretic Peptide, C-Type
  • Testosterone

Associated data

  • ClinicalTrials.gov/NCT04006171